BeOne Medicines Ltd.

XNASHealth care

Last traded price · USD

$378.02

+6.48%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 4 Nov 2026, 14:34 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $355.00
Volume: 10,630
Day's high: —
Day's low: —

In brief

BeOne Medicines Ltd. is a health care company listed on Nasdaq, valued at about $42.76B.
Its shares closed at $355.00 on 3 Nov 2026, up 13.8% over the past year.
From India you can buy ONC in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy BeOne Medicines Ltd. (ONC) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole ONC share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade ONC options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY, behind its sector fund XLV over 1 year
1 month: −1.8% (SPY −2.6%, XLV +9.9%). 3 months: +9.9% (SPY −2.2%, XLV +13.5%). 1 year: +13.8% (SPY +10.4%, XLV +27.4%). Price change to the 3 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ONC, SPY and XLV · as of 3 Nov 2026
Below its 50-day average, above its 200-day
The 3 Nov 2026 close of $355.00 was 2.1% below its 50-day average ($362.54) and 9.2% above its 200-day average ($325.11). It has closed above the 200-day for 65 sessions, since 4 Aug 2026. The 50-day average crossed above the 200-day on 25 Aug 2026, 49 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 3 Nov 2026
75% of the way up its 52-week range
Closed at $355.00 on 3 Nov 2026: 8.7% below the 52-week high of $388.66 (21 Oct 2026) and 39.8% above the low of $253.95 (11 Jun 2026).
Daily price bars, split-adjusted · as of 3 Nov 2026
Short interest at 1.6% of shares outstanding
1.8M shares were sold short at the 15 Oct 2026 settlement, 1.6% of the 109.8M shares outstanding; covering them would take 4.9 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 3 Nov 2026 close

1 month−1.8%

6 months+19.3%

1 year+13.8%

5 years—

Newswire

About

Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes mainly with AbbVie and AstraZeneca. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.

Website

Notable moves

September 10, 2025
−10.59%
April 22, 2025
+10.27%
April 11, 2025
+10.59%

Newswire

About

Website

Notable moves

September 10, 2025
−10.59%
April 22, 2025
+10.27%
April 11, 2025
+10.59%

BeOne Medicines Ltd.

XNASHealth care

Last traded price · USD

$378.02

+6.48%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 4 Nov 2026, 14:34 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $355.00
Volume: 10,630
Day's high: —
Day's low: —

In brief

BeOne Medicines Ltd. is a health care company listed on Nasdaq, valued at about $42.76B.
Its shares closed at $355.00 on 3 Nov 2026, up 13.8% over the past year.
From India you can buy ONC in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy BeOne Medicines Ltd. (ONC) shares from India?

Do I need the price of a whole ONC share to invest?

How much can I invest in US stocks in a year?

Can I trade ONC options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY, behind its sector fund XLV over 1 year
1 month: −1.8% (SPY −2.6%, XLV +9.9%). 3 months: +9.9% (SPY −2.2%, XLV +13.5%). 1 year: +13.8% (SPY +10.4%, XLV +27.4%). Price change to the 3 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ONC, SPY and XLV · as of 3 Nov 2026
Below its 50-day average, above its 200-day
The 3 Nov 2026 close of $355.00 was 2.1% below its 50-day average ($362.54) and 9.2% above its 200-day average ($325.11). It has closed above the 200-day for 65 sessions, since 4 Aug 2026. The 50-day average crossed above the 200-day on 25 Aug 2026, 49 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 3 Nov 2026
75% of the way up its 52-week range
Closed at $355.00 on 3 Nov 2026: 8.7% below the 52-week high of $388.66 (21 Oct 2026) and 39.8% above the low of $253.95 (11 Jun 2026).
Daily price bars, split-adjusted · as of 3 Nov 2026
Short interest at 1.6% of shares outstanding
1.8M shares were sold short at the 15 Oct 2026 settlement, 1.6% of the 109.8M shares outstanding; covering them would take 4.9 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 3 Nov 2026 close

1 month−1.8%

6 months+19.3%

1 year+13.8%

5 years—

Newswire

About

Website

Notable moves

September 10, 2025
−10.59%
April 22, 2025
+10.27%
April 11, 2025
+10.59%

Newswire

About

Website

Notable moves

September 10, 2025
−10.59%
April 22, 2025
+10.27%
April 11, 2025
+10.59%

BeOne Medicines Ltd.

BeOne Medicines Ltd. in brief

Ahead of SPY, behind its sector fund XLV over 1 year

Below its 50-day average, above its 200-day

75% of the way up its 52-week range

Short interest at 1.6% of shares outstanding

BeOne Medicines Ltd.

BeOne Medicines Ltd. in brief

Ahead of SPY, behind its sector fund XLV over 1 year

Below its 50-day average, above its 200-day

75% of the way up its 52-week range

Short interest at 1.6% of shares outstanding